Mycophenolic acid in psoriasis

Area of Science:

• Immunology
• Dermatology
• Pharmacology

Background:

• Mycophenolic acid (MPA) is a potent inhibitor of nucleic acid synthesis.
• MPA demonstrates antitumour activity by targeting purine biosynthesis pathways.
• In vivo efficacy of MPA is linked to beta-glucuronidase activity in epithelial tissues.

Purpose of the Study:

• To evaluate the efficacy and safety of Mycophenolic acid (MPA) in treating severe psoriasis.
• To compare the therapeutic effects of MPA against a placebo in a double-blind clinical trial.

Main Methods:

• A double-blind, placebo-controlled study involving 28 patients with psoriasis.
• Assessment of disease severity scores before and after treatment with MPA or placebo.
• Cross-over design to evaluate MPA efficacy after initial placebo treatment and vice versa.

Main Results:

• MPA treatment resulted in a 56% improvement in mean severity scores, significantly outperforming the 9% improvement with placebo.
• Patients switched to MPA from placebo showed an 86% improvement, while those switched to placebo from MPA worsened by 70%.
• Approximately 75% of patients receiving MPA experienced good to excellent responses with low toxicity.

Conclusions:

• Mycophenolic acid demonstrates significant efficacy in treating severe psoriasis.
• MPA offers a promising therapeutic option for psoriasis management with a favorable safety profile.